Skip to main content
Delfa

← All trials/NCT02832999

LIRAVIS

CompletedPhase 4

Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes

Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in a Sub Saharan African Population With Type 2 Diabetes

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

-

Actual enrollment

14

Study population

Type 2 diabetes

Eligibility highlights

•HbA1c ≥7%

Primary endpoint

•Insulin sentivity

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02832999
Org study IDCNO20163

Timeline

Milestones

Study first posted2016-07-14estimated
Last update posted2017-12-26actual
Study start2016-01actual (month precision)
Primary completion2016-09actual (month precision)
Study completion2016-12actual (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age21 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetes mellitus known for at least one year
•Uncontrolled glycaemic profile with HbA1c ≥ 7% on oral antidiabetic mono or bi-therapy
•Naïve of incretinomimetic treatment
•Informed consent

Exclusion criteria

•Change in antidiabetic treatment less than 3 months prior to inclusion
•Pancreatitis
•Alanine amino transferase > 3 times the normal values
•Pregnant or breastfeeding women
•Estimated glomerular filtration rate < 60ml/min
•Infection less than 10 days prior to inclusion or during the study
•Acute complication of diabetes
•Total haemoglobin < 11g/dL in women or < 13g/dL in men
•Withdrawal of consent

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
2
Cardiometabolic biomarkers
2
Weight & body composition
1
Renal / kidney
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

body weight

Time frame:2 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

Insulin sentivity

Time frame:2 weeks

change from baseline, improvement

Secondary/protocol endpoint/low confidence

insulin secretion

Time frame:2 weeks

change from baseline, improvement

Renal / kidney

1 endpoint
Other/protocol endpoint/low confidence

Renal function

Time frame:2 weeks

change from baseline, improvement

Cardiometabolic biomarkers

2 endpoints
Secondary/protocol endpoint/low confidence

lipid profile

Time frame:2 weeks

change from baseline, improvement

Other/protocol endpoint

Inflammation

Time frame:2 weeks

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.